Abstracts tagged "Cardiovascular disease"

Abstract Number: 2921 • 2017 ACR/ARHP Annual Meeting
Improved Survival Following Renal Transplantation in Waitlisted Patients with Systemic Lupus Erythematosus in the United States
April Jorge¹, Zachary S. Wallace², Na Lu³, Yuqing Zhang⁴ and Hyon K. Choi⁵, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Department of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis is a major complication of systemic lupus erythematosus (SLE), occurring in up to half all SLE patients and progressing to end-stage renal…
Abstract Number: 28 • 2017 Pediatric Rheumatology Symposium
Dyslipidemia in Juvenile Dermatomyositis
Arya Kadakia¹, Amer Khojah², Gabrielle A. Morgan^3,4, Megan L. Curran⁵, Irwin Benuck⁶, Chinag-Ching Huang¹, Dong Xu⁷ and Lauren M. Pachman^8,9, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ³Cure JM Program of Excellence in Myositis Research, Chicago, IL, ⁴Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁵Pediatric Rheumatology, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, ⁶Division of Cardiology, Northwestern University Feinberg School of Medicine, Department of Pediatrics, Chicago, IL, ⁷Program of Excellence in Cure-Juvenile Myositis (JM) Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁸Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁹Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL
Background/Purpose: Juvenile Dermatomyositis (JDM) is a multisystem pediatric autoimmune disease characterized by chronic inflammation of muscle and skin. Premature atherosclerosis is an important cause of…
Abstract Number: 21 • 2017 Pediatric Rheumatology Symposium
Enhancing Quality of Care in Childhood-Onset Systemic Lupus Erythematosus by Improving Performance on Quality Indicator Measures in Cardiovascular and Bone Health
Emily A. Smitherman¹, Adam Furnier², Janalee Taylor³, Mary Beth Burns⁴, Hermine Brunner⁵ and Esi Morgan¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH
Background/Purpose: Childhood-onset SLE (cSLE) leads to poor health outcomes, including cardiovascular and bone health, due to high rates of potentially devastating disease complications and medication…
Abstract Number: 1L • 2016 ACR/ARHP Annual Meeting
The Cardiovascular Safety of Celecoxib Versus Ibuprofen or Naproxen in 24,081 Patients with Osteoarthritis or Rheumatoid Arthritis
M. Elaine Husni¹, Daniel H. Solomon², Katherine E Wolski³, Lisa M Wisniewski³, Steven E Nissen⁴ and on behalf of the PRECISION Trial Investigators, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ⁴Cardiovascular Medicine, Chair, Cleveland Clinic, Cleveland, OH

*Both authors (Husni, Solomon)　contributed equally and will co present Background/Purpose: The relative cardiovascular (CV) safety of non-selective NSAIDs and selective COX-2 NSAIDs remains unclear. Given…
Abstract Number: 29 • 2016 ACR/ARHP Annual Meeting
Risk of Vascular Mortality in Seniors with New-Onset Rheumatoid Arthritis
Jessica Widdifield¹, Michael Paterson², Anjie Huang³, Bindee Kuriya⁴, Carter Thorne⁵, Janet E. Pope⁶, Claire Bombardier⁷ and Sasha Bernatsky⁸, ¹McGill University, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: RA patients are known to be at increased risk of vascular morbidity and mortality, although conflicting reports exist for incident RA patients. Our aim…
Abstract Number: 877 • 2016 ACR/ARHP Annual Meeting
Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Matthew J. Koster², Kenneth J. Warrington³ and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN, ³Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN
Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-analysis Background/Purpose: Several chronic inflammatory disorders, such as rheumatoid arthritis and…
Abstract Number: 1474 • 2016 ACR/ARHP Annual Meeting
Increased Levels of Lipoprotein(a) in RA Patients with Cardiovascular Disease
Sverre Holm^1,2, Ingvild Oma³, Tor-Arne Hagve⁴, Kjell Saatvedt⁵, Knut Mikkelsen⁶, Hans Rydningen⁷, Sven Martin Almdahl⁸, Pål Aukrust^9,10, Bente Halvorsen^9,11 and Ivana Hollan^6,12,13,14, ¹Hospital For Rheumatic Diseases, Lillehammer, Norway, ²Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ³Innlandet Hospital Trust, Lillehammer, Norway, ⁴Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁵Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁷Feiring Heart Clinic, Feiring, Norway, ⁸Department of Cardiothoracic Surgery, University Hospital of North Norway, Tromsø, Norway, ⁹Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ¹⁰Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹¹Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ¹²Department of Medicine, Brigham and Women’s Hospital, Boston, MA, ¹³Harvard Medical School, Boston, MA, ¹⁴Department of Medicine, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with various inflammatory rheumatic diseases (IRD) have increased cardiovascular morbidity caused by atherosclerosis. The aetiology of the accelerated atherosclerosis in IRD is still…
Abstract Number: 1653 • 2016 ACR/ARHP Annual Meeting
Delineating the Effects of Rheumatoid Arthritis Pharmacotherapies on Vascular Inflammation: Rationale and Design of a Clinical Trial
Jon T. Giles¹, Katherine Liao², Nina Paynter³, Alyssa Wohlfahrt⁴, Afshin Zartoshti⁵, Rachel Broderick⁶, Daniel H. Solomon⁷ and Joan Bathon⁶, ¹Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ²Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ³Medicine, Harvard University, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology, Columbia University, College of Physicians & Surgeons, New York city, NY, ⁶Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁷Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis is associated with an excess cardiovascular disease (CVD) burden. Fewer CVD events associated with specific DMARD therapies have been reported; however, causal…
Abstract Number: 2291 • 2016 ACR/ARHP Annual Meeting
Impact of Plasma Urate and Tophaceous Burden on Inflammatory Biomarkers of Cardiovascular Disease
John FitzGerald¹, Benjamin D. Levine², Jennifer Raymond³ and Maureen A. McMahon¹, ¹Rheumatology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ³Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Gout and hyperuricemia have been associated with cardiovascular disease. Studies have documented the impact of serum urate levels on hypertension and that increased urate…
Abstract Number: 69 • 2016 ACR/ARHP Annual Meeting
IL-32 Promoter SNP rs4786370 Predisposed to Modified Lipoprotein Profiles in Patients with Rheumatoid Arthritis
Michelle S.M.A. Damen¹, Rabia Agca², Suzanne Holewijn³, Jacqueline de Graaf¹, Jéssica C. Dos Santos^1,4, Piet L van Riel⁵, J Fransen⁶, Marieke J.H. Coenen⁷, Mike T. Nurmohamed⁸, M.G. Netea¹, Charles Dinarello⁹, L.A.B. Joosten¹, Bas Heinhuis¹ and Calin Popa¹⁰, ¹Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, Location Reade, Amsterdam, Netherlands, ³Rijnstate Ziekenhuis, Arnhem, Netherlands, ⁴Instituto de Patologia Tropical e Saúde Pública, Goiás, Brazil, ⁵Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, Netherlands, ⁶Department of Rheumatolgy, Radboud UMC, Nijmegen, Netherlands, ⁷Human Genetics (855), Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁸Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁹Department of Medicine, Division of Infectious Diseases, University of Colorado, Denver, CO, ¹⁰Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Patients with a chronic inflammatory disease such as rheumatoid arthritis (RA) are at higher risk of developing cardiovascular diseases (CVD). Interleukin (IL)-32 has previously…
Abstract Number: 881 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Involvement in Takayasu Arteritis
David Brennan¹, Kenneth J. Warrington², Jean Schmidt³, Cynthia S. Crowson⁴ and Matthew J. Koster⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine and RECIF, Amiens University Hospital, Amiens, France, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN, ⁵Rheumatology, University of California Los Angeles, CA, USA Mayo Clinic, Rochester, MN
Background/Purpose: Takayasu arteritis (TAK) is an inflammatory large-vessel vasculitis of unknown etiology affecting the proximal aorta and its primary branches. Heart disease is a major…
Abstract Number: 1475 • 2016 ACR/ARHP Annual Meeting
Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Non-Selective Nsaids in Taiwanese Rheumatoid Arthritis Patients
Tzu-Chieh Lin¹, Daniel H. Solomon², Sara K. Tedeschi¹, Kazuki Yoshida³ and Yea-Huei Kao Yang⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, Boston, MA, ³Department of Epidemiology, Harvard School of Public Health, Boston, MA, ⁴College of Medicine, National Cheng Kung University, Institute of Clinical Pharmacy and Pharmaceutical Science, Taian, Taiwan
Background/Purpose: Topical NSAIDs (tNSAIDs) have less systemic absorption than oral NSAIDs (oNSAIDs). Thus, tNSAIDs may be associated with a reduced cardiovascular disease (CVD) risk compared…
Abstract Number: 1714 • 2016 ACR/ARHP Annual Meeting
Risk of 10-Year Cardiovascular Disease Assessed By Framingham Risk Score Is Similar in Patients with Psoriatic Arthritis and Psoriasis As Assessed By Atherosclerotic Cardiovascular Disease and Framingham Risk Scores
Natsumi Ikumi¹, Agnes Szentpetery¹, Brian Kirby² and Oliver FitzGerald¹, ¹St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ²St. Vincent's University Hospital, Department of Dermatology, Dublin, Ireland
Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (PsO) are at increased risk of cardiovascular diseases (CVD) and the risk is higher in patients with…
Abstract Number: 2293 • 2016 ACR/ARHP Annual Meeting
Cardiometabolic Risk and Subclinical Urate Deposits in Patients with Symptomatic Hyperuricemia and Metabolic Syndrome
Seoyoung C. Kim¹, Rajesh Garg², Stacy Smith³, Alyssa Wohlfahrt⁴, Anarosa Campos⁵, Kathleen Vanni⁴, Lauren K Lee⁶, Penny Wang⁶, Zhi Yu⁷, Marcelo Di Carli⁸ and Daniel H. Solomon⁹, ¹Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ²Endocrinology, Brigham & Women's Hospital, Boston, MA, ³Radiology/Division of Musculoskeletal Imaging & Intervention, Brigham & Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Rheumatology Immunology & Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Nuclear Medicine, Brigham and Women's Hospital, Boston, MA, ⁹Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Elevated serum uric acid (sUA) levels, with and without gout, are associated with systemic inflammation, coronary artery disease (CAD), chronic kidney disease, and diabetes.…
Abstract Number: 128 • 2016 ACR/ARHP Annual Meeting
Call to Action: Cardiovascular Comorbidities in Medicare Rheumatology Beneficiaries
Gurjit S. Kaeley¹ and Sunita Dodani², ¹University of Florida, Ponte Vedra Beach, FL, ²Cardiology and Epidemiology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL
Background/Purpose: Cardiovascular (CV) manifestations of Rheumatological inflammatory diseases have become increasingly recognized, and, in some patients, might even constitute the initial presentation of a Rheumatological…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].